Smartlab Europe

News

Cellefill, a new integrated solution to fast-track cell, gene and biological therapies

Aseptic fill/finish experts Flexicon Liquid Filling, part of Watson-Marlow Fluid Technology Solutions (WMFTS), and barrier technology specialists Franz Ziel GmbH, announces Cellefill™, a turnkey, vial fill/finish system with an integrated barrier solution. Enhancing good manufacturing practice (GMP), customer compliance and...

Gene-Edited Neutrophils Show Potential Against Lung Cancer

In Hong Kong, lung cancer continues to be the most prevalent form of cancer. Despite its status as a prominent global cause of cancer-related deaths, there is still a need for a significant breakthrough in its treatment. The Faculty...

Telix Opens $21.2M European Radiopharmaceutical Production Facility

Telix Pharmaceuticals Limited opened Telix Manufacturing Solutions, the company's radiopharmaceutical production facility located in Belgium. The 2,800 square meter facility is one of Europe's largest radiopharmaceutical production facilities, according to the company. It will serve as Telix’s primary manufacturing site...

Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration

Charles River Laboratories International, Inc. and the INADcure Foundation, a nonprofit organization whose mission is to support the development of treatments for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related neurodegeneration (PLAN), today announced a plasmid DNA manufacturing...

Quell Therapeutics, AstraZeneca Partner on Engineered Treg Cell Therapies

Quell Therapeutics Ltd, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announced that it has entered into a collaboration, exclusive option and license agreement with AstraZeneca to develop, manufacture...

Pharma Dealmaking Recovery Gets Boosted By $85bn M&A Splurge

It is well to be noted that pharma and biotech companies splurged a whopping $85 billion in the first five months of 2023, which itself went on to mark a dramatic recovery when it comes to dealmaking as they...

Lack of Experience Hinders CDMOs In Cell And Gene Therapy

CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy manufacturing for Phase III trials and commercialization. While physical capacity has been blamed, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »